Canada markets closed

CSPC Pharmaceutical Group Limited (CVG.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.6886+0.0014 (+0.20%)
At close: 08:07AM CEST

CSPC Pharmaceutical Group Limited

No. 226 Huanghe Street
Shijiazhuang 050035
86 31 1870 37015

IndustryDrug Manufacturers - General
Full Time Employees23,500

Key Executives

NameTitlePayExercisedYear Born
Mr. Dongchen CaiExecutive Chairman2.34MN/A1954
Mr. Cuilong ZhangVice-Chairman & CEO1.24MN/A1969
Mr. Chunlei LiExecutive Director & Chief Scientist846.72kN/A1976
Mr. Weidong PanExecutive Director450.02kN/A1969
Mr. Huaiyu WangExecutive Director553.14kN/A1963
Mr. Zhenguo WangExecutive Director447.88kN/A1970
Dr. Hao JiangExecutive Director336.41kN/A1984
Mr. Xin CaiGroup Executive President, President of the Group's Marketing Strategy Division & Executive DirectorN/AN/A1991
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, North America, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company has a strategic partnership with Pfizer Inc. to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

Corporate Governance

CSPC Pharmaceutical Group Limited’s ISS Governance QualityScore as of July 1, 2024 is 8. The pillar scores are Audit: 7; Board: 6; Shareholder Rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.